The updated results show that the spread of PrEP in France is continuing and intensifying.
Thus, the number of people aged 15 and over who started a treatment with Truvada® or generics for PrEP since 2016 reached 20,478 as of June 30, 2019, i.e. twice the one reached in late June 2018. The vast majority (80 to 85 %) of users renew their treatment from one semester to another, suggesting a good level of maintenance of PrEP after its initiation.
PrEP users are mainly men who have sex with men, aged 37 on average, living in Ile-de-France area or in a large metropolis. The use of PrEP remains rare in the French overseas departments and territories, where, moreover, new diagnoses of seropositivity are the most numerous.
In accordance with the current prescription conditions, the initiation of PrEP is mostly done in hospitals (90% of cases). The same is true for its renewal (85% of cases).
This study highlights a strong increase in PrEP initiations during the recent period and provides elements in favor of a good level of maintenance of treatment after its initiation.
This study also shows that the spread of PrEP in France is continuing and intensifying. The indicators measured illustrate the real appropriation of this prevention strategy in France, in particular among men having sex with men at high risk of acquiring HIV.
However, there is still room for improvement and efforts must be continued to ensure the greatest accessibility to PrEP for all the populations concerned in France.
Find the study report the use of Truvada® or generics for pre-exposure prophylaxis (PrEP) for HIV